Myeloma Paper of the Day, June 26th, Suggested by Robert Orlowski
Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Patients with >8.7 mos between last exposure to prior BCMA-directed therapy and teclistamab have significantly improved median PFS with tec (8.1 mos, 95% CI: 4.6-11.7) vs. pts with <8.7 mos (2.5 ms, 95% CI: 1.1-5.7), p=0.001.”
Title: Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Authors: Danai Dima, Mariola A. Vazquez-Martinez, James A. Davis, Utkarsh Goel, Aimaz Afrough, Aishwarya Sannareddy, Oren Pasvolsky, Beatrice Razzo, Rahul Banerjee, Jack Khouri, Ariel Grajales-Cruz, Alex Lieberman-Cribbin, Masooma Shifa Rana, Kelley Julian, Shaun DeJarnette, Andrew J. Portuguese, Mahmoud R. Gaballa, Gabriel De Avila, Sandra Susaniba Adaniya, Shahzad Raza, Megan M. Herr, Evguenia Ouchveridze, Tiffany Richards, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Omar Castaneda Puglianini, Adriana Rossi, Yi Lin, Shebli Atrash, Douglas Sborov, Kenneth H. Shain, Peter M. Voorhees, Shambavi Richard, Alfred L. Garfall, Doris K. Hansen, Surbhi Sidana, Krina K. Patel, Andrew J. Cowan, Larry D. Anderson Jr, Hans C. Lee, Faiz Anwer, Christopher J. Ferreri, Leyla Shune.
You can read the Full Article in Blood Cancer Journal.
More posts featuring Robert Orlowski.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023